Results 181 to 190 of about 19,015 (258)
Isohemagglutinins exhibit synergistic polyreactivity toward Streptococcus pneumoniae surface antigens: implications for broad-spectrum reactivity of human antibodies. [PDF]
Bernth Jensen JM +7 more
europepmc +1 more source
Abstract Background Immunoglobulin products are widely used for the treatment of immunodeficiency and autoimmune disorders. Although clinical trials have demonstrated their efficacy and tolerability, data describing their postmarketing safety profile in pediatric populations remain limited, particularly regarding rare and serious adverse events.
Shaokui Wei +4 more
wiley +1 more source
Classic Coagulation Traits Vary According to Rh(D) (But Not ABO) Blood Groups. [PDF]
Morais-Junior GS +6 more
europepmc +1 more source
Abstract Background Immunomodulatory consequences of transfusion, known as transfusion‐related immune modulation (TRIM), impact patients but are not captured by hemovigilance systems. This study's objective is to explore TRIM impacts of production changes made by the blood supplier. Methods We included all transfused and non‐transfused adult inpatients
S. Ning +15 more
wiley +1 more source
Blood group antigens and malaria susceptibility. [PDF]
Liu FF, Liang J, Gao M, Li K.
europepmc +1 more source
Abstract Background The storage of red blood cells (RBCs) is essential for transfusion but leads to storage lesions that compromise RBC quality and increase the risk of transfusion‐related adverse effects, including allergic transfusion reactions (ATRs). Understanding storage‐induced metabolic change is crucial for enhancing transfusion safety.
Gürkan Bal +5 more
wiley +1 more source
No naturally occurring blood group antibodies were detected in the crossmatching of 25 giant pandas. [PDF]
Yin Y +19 more
europepmc +1 more source
Exploring the immunomodulatory impacts of blood manufacturing consolidation
Abstract Introduction The immunomodulatory consequences of blood transfusion, known as transfusion‐related immune modulation (TRIM), are often not captured by hemovigilance systems. Changes to blood product manufacturing processes may impact patient outcomes.
Amanda Kauffman +11 more
wiley +1 more source
Glycan-binding specificities of anti-ABO(H) antibodies and lectins. [PDF]
Hamm P +9 more
europepmc +1 more source

